US Real-world Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab

被引：0
|
作者：
Seminerio, Michael [1 ]
Tangirala, Krishna [1 ]
Thompson, Stephen F. [1 ]
Ariely, Rinat [1 ]
Cohen, Joshua M. [1 ]
Carr, Karen [1 ]
Buse, Dawn C. [2 ]
机构：
[1] Teva Branded Pharmaceut Prod R&D Inc, Montvale, NJ USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
4289
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Real-world migraine-related health care resource utilization and costs for patients initiating fremanezumab: A US retrospective claims analysis
    Buse, D. C.
    Seminerio, M. J.
    Tangirala, K.
    Thompson, S. F.
    Ariely, R.
    Cohen, J. M.
    Carr, K.
    HEADACHE, 2021, 61 : 71 - 72
  • [2] REAL-WORLD REDUCTIONS IN MIGRAINE-RELATED HEALTH CARE RESOURCE UTILIZATION AND COSTS FOR PATIENTS INITIATING FREMANEZUMAB: A 12-MONTH RETROSPECTIVE US CLAIMS ANALYSIS
    Driessen, M. T.
    Krasenbaum, L. J.
    Ramirez-Campos, V
    DiEgidio, R.
    Tian, M.
    Seminerio, M. J.
    VALUE IN HEALTH, 2022, 25 (07) : S346 - S346
  • [3] Real-world Reductions in Migraine-related Healthcare Resource Utilization for German Patients Initiating Fremanezumab
    Heinze, A.
    Totev, T.
    Krasenbaum, L.
    Terasawa, E.
    Akcicek, H.
    Hipp, J.
    Sun, R.
    Yilma, B.
    Driessen, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 420 - 420
  • [4] Impact of Fremanezumab on Migraine-related Health Care Resource Utilization and Costs in US Patients With Migraine and Comorbid Depression and/or Anxiety
    Buse, Dawn C.
    Driessen, Maurice T.
    Krasenbaum, Lynda J.
    Akcicek, Hasan
    Lyras, Leonidas
    Packnett, Elizabeth R.
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 78 - 79
  • [5] Real-world Reductions in Monthly Migraine Days and Migraine-Related Healthcare Resource Utilization in UK Patients Using Fremanezumab
    Afridi, S.
    Totev, T.
    Krasenbaum, L. J.
    Terasawa, E.
    Akcicek, H.
    Dhiraj, D.
    Sun, R.
    Yilma, B.
    Driessen, M. T.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [6] Real-world Reductions in Monthly Migraine Days and Migraine-Related Healthcare Resource Utilization in UK Patients Using Fremanezumab
    Afridi, Shazia
    Totev, Todor I.
    Krasenbaum, Lynda J.
    Terasawa, Emi
    Akcicek, Hasan
    Dhiraj, Dalbir
    Sun, Rochelle
    Yilma, Binyam
    Driessen, Maurice T.
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 74 - 75
  • [7] Real-world impact of fremanezumab on migraine-related health care utilization and costs in patients with common comorbidities, acute medication overuse, or difficult-to-treat migraine
    Buse, D. C.
    Driessen, M. T.
    Krasenbaum, L. J.
    Seminerio, M. J.
    Carr, K.
    Ortega, M.
    Packnett, E. R.
    HEADACHE, 2022, 62 : 80 - 81
  • [8] Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response
    Buse, Dawn C.
    Krasenbaum, Lynda J.
    Seminerio, Michael J.
    Packnett, Elizabeth R.
    Carr, Karen
    Ortega, Mario
    Driessen, Maurice T.
    PAIN AND THERAPY, 2024, 13 (03) : 511 - 532
  • [9] Real-world reductions in migraine-related healthcare resource utilization and medication use with fremanezumab treatment in US migraine patients using concomitant acute gepants
    Eugeni, P.
    Rooney, M. E.
    Saikali, N. P.
    Niu, Z.
    Driessen, M. T.
    Krasenbaum, L. J.
    Seminerio, M. J.
    McVige, J. W.
    HEADACHE, 2022, 62 : 158 - 158
  • [10] Reductions in acute medication use, migraine-related health care resource utilization, and costs for patients initiating fremanezumab: Results of a long-term US claims database analysis
    Krasenbaum, L. J.
    Driessen, M. T.
    Campos, Ramirez V.
    Tian, M.
    Seminerio, M. J.
    Carr, K.
    DiEgidio, R.
    HEADACHE, 2022, 62 : 83 - 84
12345